Advertisement
UK markets closed
  • FTSE 100

    8,433.76
    +52.41 (+0.63%)
     
  • FTSE 250

    20,645.38
    +114.08 (+0.56%)
     
  • AIM

    790.50
    +6.80 (+0.87%)
     
  • GBP/EUR

    1.1627
    +0.0016 (+0.14%)
     
  • GBP/USD

    1.2526
    +0.0002 (+0.02%)
     
  • Bitcoin GBP

    48,689.18
    -901.04 (-1.82%)
     
  • CMC Crypto 200

    1,264.07
    -93.94 (-6.92%)
     
  • S&P 500

    5,216.70
    +2.62 (+0.05%)
     
  • DOW

    39,450.64
    +62.88 (+0.16%)
     
  • CRUDE OIL

    78.98
    -0.28 (-0.35%)
     
  • GOLD FUTURES

    2,371.70
    +31.40 (+1.34%)
     
  • NIKKEI 225

    38,229.11
    +155.13 (+0.41%)
     
  • HANG SENG

    18,963.68
    +425.87 (+2.30%)
     
  • DAX

    18,772.85
    +86.25 (+0.46%)
     
  • CAC 40

    8,219.14
    +31.49 (+0.38%)
     

SAGE Therapeutics’ GABA Receptor–Based Portfolio

SAGE Therapeutics’ GABA Receptor–Based Portfolio

As we discussed earlier, SAGE Therapeutics’ (SAGE) portfolio includes the products it has under development for the treatment of life-threatening central nervous system disorders based on either GABA (gamma-Aminobutyric acid) or NMDA (N-methyl-D-aspartate) receptor systems.